Inventor · disambiguated record
Myrna A. Monck
Also filed as: MONCK MYRNA · MONCK MYRNA A
11 granted patents·6 pending applications·144 citations·filing 1997–2024
90Inventor score
Files withGLAXOSMITHKLINE IP NO 2 LTD10GLAXOSMITHKLINE IP DEV LTD2MONCK MYRNA A2UNIV BRITISH COLUMBIA2
Top patents by PatentIndex Score
17 records- 0195US11459384B2Biopharmaceutical compositionsGLAXOSMITHKLINE IP NO 2 LTD·Filed 2022·Granted Oct 4, 2022·3 cites·25 claims
- 0294US11299541B2Biopharmaceutical compositionsGLAXOSMITHKLINE IP NO 2 LTD·Filed 2021·Granted Apr 12, 2022·3 cites·19 claims
- 0394US11286298B2Biopharmaceutical compositionsGLAXOSMITHKLINE IP NO 2 LTD·Filed 2021·Granted Mar 29, 2022·3 cites·17 claims
- 0494US11274148B2Biopharmaceutical compositionsGLAXOSMITHKLINE IP NO 2 LTD·Filed 2021·Granted Mar 15, 2022·3 cites·18 claims
- 0592US10870695B2Biopharmaceutical compositions comprising interleukin-5 antibodyGLAXOSMITHKLINE IP NO 2 LTD·Filed 2016·Granted Dec 22, 2020·8 cites·12 claims
- 0692US6417326B1Fusogenic liposomesUNIV BRITISH COLUMBIA·Filed 1997·Granted Jul 9, 2002·118 cites·3 claims
- 0788US12187790B2Biopharmaceutical compositionsGLAXOSMITHKLINE IP NO 2 LTD·Filed 2024·Granted Jan 7, 2025·0 cites·17 claims
- 0888US12187791B2Biopharmaceutical compositionsGLAXOSMITHKLINE IP NO 2 LTD·Filed 2024·Granted Jan 7, 2025·0 cites·17 claims
- 0988US12187789B2Biopharmaceutical compositionsGLAXOSMITHKLINE IP NO 2 LTD·Filed 2024·Granted Jan 7, 2025·0 cites·22 claims
- 1083US12454571B2Biopharmaceutical compositionsGLAXOSMITHKLINE IP NO 2 LTD·Filed 2022·Granted Oct 28, 2025·0 cites·13 claims
- 1181US7205273B2Fusogenic liposomesUNIV BRITISH COLUMBIA·Filed 2002·Granted Apr 17, 2007·6 cites·3 claims
- 1271US2020199219A1Biopharmaceutical compositionsGLAXOSMITHKLINE IP NO 2 LTD·Filed 2020·Application pending·0 cites
- 1362US2025042985A1Interleukin 5 binding protein dosage regimen for use in treating polyangiitis, hypereosinophilic syndrome, chronic rhinosinusitis with nasal polyps (crswnp), or chronic rhinosinusitis without nasal polyps (crssnp)GLAXOSMITHKLINE IP DEV LTD·Filed 2022·Application pending·0 cites
- 1458US2024043524A1Interleukin 5 binding protein dosage regimenGLAXOSMITHKLINE IP DEV LTD·Filed 2021·Application pending·0 cites
- 1547US2014023655A1Formulations with reduced viscosityMONCK MYRNA A·Filed 2012·Application pending·0 cites
- 1640US2014044727A1Formulations with reduced viscosityMONCK MYRNA A·Filed 2012·Application pending·0 cites
- 1738US2004013720A1Receptor antagonist-lipid conjugates and delivery vehicles containing sameFiled 2003·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →